With a budgetary increase of $297 million in FY2020, NCI anticipates funding more than 125 additional competing awards over FY19 levels—and devoting more than $210 million in new funding to support extramural research and training opportunities.
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
